Share this video  

ESMO Sarcoma and Rare Cancers | NET subgroups dictate immunotherapy response

Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, talks on different neuroendocrine tumor (NET) subgroups and the importance of the tumor microenvironment and niche in dictating responses to immunotherapy treatment. Research has found immunotherapy to be ineffective in grade 1/grade 2 (G1/G2) NET treatment and gastrointestinal (GI) tumors, whilst more effective in other subgroups. Some basket trials have shown using dual blockade with nivolumab and ipilimumab to be more effective in treating lung NETs. Phase II trials suggest mutations such as Rep1a and BRCA could predict a response to checkpoint inhibitor treatment. Dr Garcia-Carbonero notes that despite this, more follow up is required to assess durability of response rate and to investigate different subgroups where immunotherapy may be beneficial. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.